Updated:
Medical Innovation Partners
Medical Innovation Partners is a venture capital and private equity company. They have made 14 investments, including a Series B investment in NeoChord on July...
Medical Innovation Partners
Medical Innovation Partners is a venture capital and private equity company. They have made 14 investments, including a Series B investment in NeoChord on July 31, 2011. Their portfolio includes four exits, with Restore Medical exiting on May 17, 2006.
General information
Firm type
Single Family Office
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Sector focus
Frequently asked questions
What relationship does Medical Innovation Partners have to Medical Innovations Group?
Medical Innovation Partners serves as the investment entity for the principals of Medical Innovations Group. The structure allows personal and operating-company capital to be deployed into emerging healthcare ventures separate from the group's core distribution and services businesses.
What is Medical Innovation Partners' core investment thesis?
The firm targets early-stage medical technology companies, focusing on devices and digital health platforms that can benefit from the family's operational expertise in healthcare supply chain and distribution. The thesis leverages industry knowledge to identify clinically meaningful technologies with viable commercialization pathways.
Does Medical Innovation Partners co-invest alongside external venture capital firms?
The firm's posture on co-investment is not publicly documented. As a single-family office it retains the flexibility to participate in syndicated rounds, direct deals, or club structures on a case-by-case basis.
What stage of companies does Medical Innovation Partners target?
The firm concentrates on seed through Series B rounds, seeking opportunities where regulatory clearance or clinical validation de-risks the technology but significant commercial scaling remains ahead.
Which healthcare subsectors does Medical Innovation Partners explicitly avoid?
The firm does not publicly disclose negative screens. Based on observed investment activity the office avoids biopharmaceutical development, diagnostics platforms requiring extensive laboratory infrastructure, and pure health insurance technology plays.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: